City

Condition

Familial Hypercholesterolemia (2)

Homozygous Sitosterolemia (2)

Hypercholesterolemia (2)

Overall Status

Completed (2)

Sign in for free

Phase

Sponsor

Organon and Co (2)

Collaborator

Bayer (2)

Intervention

ezetimibe (2)

ezetimibe + other lipid-lowering medication(s) (2)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Observational (2)

homozygous sitosterolemia

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

A 52-week Post-marketing, Observational Study to Confirm Safety

Completed

Hypercholesterolemia
+2 more

Ezetimibe
Ezetimibe + other lipid-lowering medication(s)

(no location specified)

Feb 7, 2022

A 12-week Post-marketing, Observational Study to Confirm Safety

Completed

Hypercholesterolemia
+2 more

Ezetimibe
Ezetimibe + other lipid-lowering medication(s)

(no location specified)

Feb 7, 2022